BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M, Yoneda M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12(2): 322-326 [PMID: 16482638 DOI: 10.3748/wjg.v12.i2.322] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Warner F, Lubel J, Mccaughan G, Angus P. Liver fibrosis: a balance of ACEs? Clinical Science 2007;113:109-18. [DOI: 10.1042/cs20070026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
2 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther. 2008;25:1141-1174. [PMID: 18972077 DOI: 10.1007/s12325-008-0110-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
4 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504 [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
5 Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54:1631-1639. [PMID: 21748770 DOI: 10.1002/hep.24558] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 12.8] [Reference Citation Analysis]
6 Zhang QZ, Liu YL, Wang YR, Fu LN, Zhang J, Wang XR, Wang BM. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med. 2017;14:2689-2694. [PMID: 28962213 DOI: 10.3892/etm.2017.4809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chitturi S. Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol 2008;1:173-89. [PMID: 21180527 DOI: 10.1177/1756283X08096951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 申月明, 朱萱. 肝星状细胞激活与信号转导. 世界华人消化杂志 2007; 15(8): 873-878 [DOI: 10.11569/wcjd.v15.i8.873] [Reference Citation Analysis]
9 Strahl S, Maier KP. [Are there therapeutic approaches of non-alcoholic fatty liver disease and its complications?]. Internist (Berl) 2008;49:1421-2, 1424-7. [PMID: 19002423 DOI: 10.1007/s00108-008-2151-7] [Reference Citation Analysis]
10 Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, Hirose H, Ebinuma H, Irie J, Ojiro K. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013;2013:587140. [PMID: 23997767 DOI: 10.1155/2013/587140] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
11 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
12 Lubel JS, Herath CB, Velkoska E, Casley DJ, Burrell LM, Angus PW. Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology 2008;58:119-26. [PMID: 19224387 DOI: 10.1007/s10616-009-9185-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci. 2011;56:564-568. [PMID: 21136163 DOI: 10.1007/s10620-010-1507-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
14 Duvnjak M, Baršić N, Tomašić V, Lerotić I. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression. World J Gastroenterol 2009; 15(48): 6023-6027 [PMID: 20027673 DOI: 10.3748/wjg.15.6023] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
15 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 17.9] [Reference Citation Analysis]
16 Della Corte C, Alisi A, Iorio R, Alterio A, Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2011;12:1901-1911. [PMID: 21639814 DOI: 10.1517/14656566.2011.587123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
17 Santos ARD, Dionizio A, Fernandes MDS, Buzalaf MAR, Pereira B, Donanzam DFA, Ribeiro SM, Paniago AMM, Cavalcante RS, Mendes RP, Venturini J. Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel. PLoS Negl Trop Dis 2021;15:e0009714. [PMID: 34424905 DOI: 10.1371/journal.pntd.0009714] [Reference Citation Analysis]
18 Guillaud O, Gurram KC, Puglia M, Lilly L, Adeyi O, Renner EL, Selzner N. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation. Transplant Proc 2013;45:2331-6. [PMID: 23953545 DOI: 10.1016/j.transproceed.2013.01.067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest. 2012;35:215-218. [PMID: 22490991 DOI: 10.1007/bf03345421] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
21 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
22 杨玲, 朱清静, 侯晓华, 胡胜军, 徐敏, 朱锐. 血管紧张素II对肝星状细胞迁移和增殖的影响. 世界华人消化杂志 2007; 15(9): 1004-1007 [DOI: 10.11569/wcjd.v15.i9.1004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Alam S, Abrar M, Islam S, Kamal M, Hasan MJ, Khan MAS, Ahmad N. Effect of telmisartan and vitamin E on liver histopathology with non-alcoholic steatohepatitis: A randomized, open-label, noninferiority trial. JGH Open 2020;4:663-9. [PMID: 32782954 DOI: 10.1002/jgh3.12315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491-503. [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
25 Park JG, Mok JS, Han YI, Park TS, Kang KW, Choi CS, Park HD, Park J. Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. Sci Rep 2019;9:4003. [PMID: 30850637 DOI: 10.1038/s41598-019-40322-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res 2018;41:394-405. [PMID: 29636553 DOI: 10.1038/s41440-018-0040-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
27 Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020;134:3137-3158. [PMID: 33284956 DOI: 10.1042/cs20201268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
28 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642. [PMID: 16912563 DOI: 10.1097/01.mco.0000241677.40170.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
29 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
30 Praveenraj P, Gomes RM, Kumar S, Karthikeyan P, Shankar A, Parthasarathi R, Senthilnathan P, Rajapandian S, Palanivelu C. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obes Surg. 2015;25:2078-2087. [PMID: 25835982 DOI: 10.1007/s11695-015-1655-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
31 Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007;23:193-8. [PMID: 17268250 DOI: 10.1097/MOG.0b013e32801421a9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
32 Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600-606. [PMID: 16899321 DOI: 10.1016/j.jhep.2006.06.013] [Cited by in Crossref: 340] [Cited by in F6Publishing: 299] [Article Influence: 22.7] [Reference Citation Analysis]
33 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
34 Charatcharoenwitthaya P, Talwalkar JA, Angulo P, Gossard AA, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. Dig Dis Sci 2010;55:476-83. [DOI: 10.1007/s10620-009-0744-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
35 Fabris C, Smirne C, Fangazio S, Toniutto P, Burlone M, Minisini R, Bitetto D, Falleti E, Cerutti A, Pirisi M. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatology Research 2009;39:795-804. [DOI: 10.1111/j.1872-034x.2009.00518.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
37 Torres DM, Harrison SA. Current treatments in nonalcoholic steatohepatitis. Curr Treat Options Gastro 2007;10:425-34. [DOI: 10.1007/s11938-007-0042-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Ye Z, Houssein HS, Mahato RI. Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides 2007;17:349-404. [PMID: 18154454 DOI: 10.1089/oli.2007.0097] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
39 Hojo M, Watanabe S. Pharmacological therapy of nonalcoholic steatohepatitis: Therapeutic value of NASH treatments. Hepatology Research 2011;41:209-16. [DOI: 10.1111/j.1872-034x.2011.00780.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016;65:1183-1195. [PMID: 27301803 DOI: 10.1016/j.metabol.2016.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
41 Ratziu V, Zelber-sagi S. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:667-88. [DOI: 10.1016/j.cld.2009.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
42 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
43 Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med (Maywood). 2011;236:557-566. [PMID: 21508249 DOI: 10.1258/ebm.2011.010375] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
44 Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141-149. [PMID: 19262374 DOI: 10.1097/med.0b013e3283293015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
45 Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26 Suppl 1:153-162. [PMID: 21199527 DOI: 10.1111/j.1440-1746.2010.06547.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 7.5] [Reference Citation Analysis]
46 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
47 Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst. 2007;24:93-146. [PMID: 17725523 DOI: 10.1615/critrevtherdrugcarriersyst.v24.i2.10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
48 Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383. [PMID: 20415685 DOI: 10.1111/j.1463-1326.2009.01176.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 14.2] [Reference Citation Analysis]
49 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
50 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 21.0] [Reference Citation Analysis]
51 Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond). 2012;123:225-239. [PMID: 22548407 DOI: 10.1042/cs20120030] [Cited by in Crossref: 55] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]
52 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
53 Brookes MJ, Iqbal TH, Cooper BT. Hypertension and hepatic steatosis. Curr Hypertens Rep 2008;10:182-7. [PMID: 18765087 DOI: 10.1007/s11906-008-0035-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
54 Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease: Treatment of NAFLD. International Journal of Clinical Practice 2010;64:968-83. [DOI: 10.1111/j.1742-1241.2009.02327.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
55 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
56 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 11.2] [Reference Citation Analysis]
57 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 110] [Article Influence: 9.8] [Reference Citation Analysis]
58 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 62] [Article Influence: 20.3] [Reference Citation Analysis]
59 Miyaoka Y, Jin D, Tashiro K, Masubuchi S, Ozeki M, Hirokawa F, Hayashi M, Takai S, Uchiyama K. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Exp Anim 2018;67:239-47. [PMID: 29311502 DOI: 10.1538/expanim.17-0126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
60 Lu P, Liu H, Yin H, Yang L. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit. 2011;17:BR248-BR256. [PMID: 21873937 DOI: 10.12659/MSM.881928] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
61 Ratziu V, Vispo M, Tahiri M, Bonyhay L, de Torres M, Bernhardt C, Poynard T, Lebray P. Peut-on traiter la stéatohépatite métabolique ? Gastroentérologie Clinique et Biologique 2007;31:333-40. [DOI: 10.1016/s0399-8320(07)89386-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol. 2008;23:1327-1338. [PMID: 18557800 DOI: 10.1111/j.1440-1746.2008.05461.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 6.2] [Reference Citation Analysis]
63 Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15(8): 942-954 [PMID: 19248193 DOI: 10.3748/wjg.15.942] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 112] [Article Influence: 10.3] [Reference Citation Analysis]
64 Alam S, Kabir J, Mustafa G, Gupta U, Hasan SK, Alam AK. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol. 2016;22:69-76. [PMID: 26831610 DOI: 10.4103/1319-3767.173762] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
65 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
66 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 25.4] [Reference Citation Analysis]
67 Rosselli MS, Burgueño AL, Carabelli J, Schuman M, Pirola CJ, Sookoian S. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009;206:119-26. [DOI: 10.1016/j.atherosclerosis.2009.01.026] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
68 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
69 Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med. 2018;33:453-461. [PMID: 29462546 DOI: 10.3904/kjim.2017.317] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
70 Wu GH, Boucher BJ, Chiu YH, Liao CS, Chen TH. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutr. 2009;12:129-135. [PMID: 18410705 DOI: 10.1017/s1368980008002073] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
71 Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol. 2009;3:257-268. [PMID: 19485808 DOI: 10.1586/egh.09.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
72 Macêdo SMD, Antunes Guimarães T, Feltenberger JD, Santos SHS. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014;62:189-96. [DOI: 10.1016/j.peptides.2014.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]